Literature DB >> 18832670

Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells.

Maria L Belladonna1, Claudia Volpi, Roberta Bianchi, Carmine Vacca, Ciriana Orabona, Maria T Pallotta, Louis Boon, Stefania Gizzi, Maria C Fioretti, Ursula Grohmann, Paolo Puccetti.   

Abstract

CD8(-) and CD8(+) dendritic cells (DCs) are distinct subsets of mouse splenic accessory cells with opposite but flexible programs of Ag presentation, leading to immunogenic and tolerogenic responses, respectively. In this study, we show that the default tolerogenic function of CD8(+) DCs relies on autocrine TGF-beta, which sustains the activation of IDO in response to environmental stimuli. CD8(-) DCs do not produce TGF-beta, yet externally added TGF-beta induces IDO and turns those cells from immunogenic into tolerogenic cells. The acquisition of a suppressive phenotype by CD8(-) DCs correlates with activation of the PI3K/Akt and noncanonical NF-kappaB pathways. These data are the first to link TGF-beta signaling with IDO in controlling spontaneous tolerogenesis by DCs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832670     DOI: 10.4049/jimmunol.181.8.5194

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  70 in total

1.  An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis.

Authors:  Jonathan J Cho; Joshua M Stewart; Theodore T Drashansky; Maigan A Brusko; Ashley N Zuniga; Kyle J Lorentsen; Benjamin G Keselowsky; Dorina Avram
Journal:  Biomaterials       Date:  2017-07-24       Impact factor: 12.479

2.  Dichotomous effects of IFN-γ on dendritic cell function determine the extent of IL-12-driven antitumor T cell immunity.

Authors:  Jamie L Harden; Tao Gu; Mehmet O Kilinc; Rachael B Rowswell-Turner; Lauren P Virtuoso; Nejat K Egilmez
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

Review 3.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

4.  Physiologic control of IDO competence in splenic dendritic cells.

Authors:  Babak Baban; Phillip R Chandler; Burles A Johnson; Lei Huang; Minghui Li; Marlon L Sharpe; Loise M Francisco; Arlene H Sharpe; Bruce R Blazar; David H Munn; Andrew L Mellor
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

Review 5.  Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.

Authors:  Diwakar Davar; Nathan Bahary
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

6.  Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy.

Authors:  Alisha Holtzhausen; Fei Zhao; Kathy S Evans; Masahito Tsutsui; Ciriana Orabona; Douglas S Tyler; Brent A Hanks
Journal:  Cancer Immunol Res       Date:  2015-06-03       Impact factor: 11.151

7.  Activation of the noncanonical NF-κB pathway by HIV controls a dendritic cell immunoregulatory phenotype.

Authors:  Olivier Manches; Melissa Victoria Fernandez; Joel Plumas; Laurence Chaperot; Nina Bhardwaj
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-09       Impact factor: 11.205

8.  IDO: more than an enzyme.

Authors:  Wanjun Chen
Journal:  Nat Immunol       Date:  2011-08-18       Impact factor: 25.606

Review 9.  Tolerogenic dendritic cells: all present and correct?

Authors:  A W Thomson
Journal:  Am J Transplant       Date:  2010-01-05       Impact factor: 8.086

10.  Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone.

Authors:  Francesca Fallarino; Giovanni Luca; Mario Calvitti; Francesca Mancuso; Claudio Nastruzzi; Maria C Fioretti; Ursula Grohmann; Ennio Becchetti; Anne Burgevin; Roland Kratzer; Peter van Endert; Louis Boon; Paolo Puccetti; Riccardo Calafiore
Journal:  J Exp Med       Date:  2009-10-12       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.